lebrikizumab AD
Selected indexed studies
- Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis. (N Engl J Med, 2023) [PMID:36920778]
- Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials. (Br J Dermatol, 2023) [PMID:36994947]
- Systemic treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials. (J Allergy Clin Immunol, 2023) [PMID:37678577]
_Worker-drafted node — pending editorial review._
Connections
lebrikizumab AD is a side effect of
Sources
- Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis. (2023) pubmed
- Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials. (2023) pubmed
- Lebrikizumab: First Approval. (2024) pubmed
- Binding, Neutralization and Internalization of the Interleukin-13 Antibody, Lebrikizumab. (2023) pubmed
- Two-Year Efficacy and Safety of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Long-Term Extension (ADjoin). (2025) pubmed
- Lebrikizumab Rapidly Lowers Inflammatory Biomarkers with Clinical Correlations in Moderate-to-Severe Atopic Dermatitis. (2025) pubmed
- Systemic treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials. (2023) pubmed
- Systemic Immunomodulatory Treatments for Atopic Dermatitis: Living Systematic Review and Network Meta-Analysis Update. (2024) pubmed
- Treatment of atopic dermatitis: Recently approved drugs and advanced clinical development programs. (2024) pubmed
- Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial (ADhere). (2023) pubmed